Plant Sterols & Stanols — Deep Evidence Review
Single source of truth: mechanism, evidence, Lp(a) interaction, and the Top 3 product picks for your phenotype.
Last updated: 25 May 2026
RCTs in pooled evidence: ~109 (Yang 2024 meta)
Cohort participants: 213,992 (NHS + HPFS)
EAS 2014: Endorsed at 2 g/day · ESC/EAS 2025 Update: Not endorsed for ASCVD risk reduction
TL;DR
- Evidence is solid for biomarkers. Plant sterols/stanols at 2 g/day → LDL-C ~−10 to −12%, ApoB −5 to −8%, TG ~−6%, SBP ~−2 mmHg. Backed by 109-RCT meta-analysis (Yang 2024) and a 213,992-person prospective cohort (Wang 2024) showing modest CAD risk reduction.
- Honest caveat: The 2025 ESC/EAS Focused Update does not endorse phytosterol supplements for ASCVD risk reduction — zero CV outcome RCTs exist. Reasonable adjunct, not a substitute for proven therapy.
- Prefer stanols (or stanol-blends) over pure sterols given your elevated Lp(a) — eliminates the oxyphytosterol-binds-Lp(a) concern. Wild-type ABCG5/8 status (confirmed via VCF) removes the genetic safety question.
- Documented psyllium synergy via hepatic LDL-receptor upregulation (+26% in mononuclear cells). These compose, not duplicate.
- Top 3 products — verified May 2026 (see Product Selection): #1 NOW Foods Beta-Sitosterol with CardioAid-S + Fish Oil (4 sg = 2 g cleanly, ~$20/mo) · #2 Nature Made CholestOff Plus (USP Verified) · #3 Solgar Phytosterol Complex (premium clean brand, 4 sg = 2 g).
- Re: stanol-preference for Lp(a): Mechanistically sound but unproven in CV outcomes. For capsule (not spread) format + your wild-type ABCG5/8, getting to 2 g/day with good adherence dominates the stanol/sterol distinction.
- Verdict for you: Add at 2 g/day with psyllium 10 g/day. Expect ApoB ~−13 to −18% combined. Re-test at 12 weeks.
Headline
Effect Sizes at 2 g/day (from Yang 2024 meta-analysis, 109 RCTs)
Verification note: Specific effect-size numbers below are from Yang 2024 abstracts and secondary citations; independent confirmation against the full Yang text was partial (May 2026 verification pass). For comparison, a 2024 umbrella review of phytosterol meta-analyses reports LDL-C ES = −11.47 mg/dL (95% CI −12.76 to −10.17) — directionally consistent, slightly smaller magnitude.
LDL-C
−12.6 mg/dL
95% CI: −13.9 to −11.3 · ~10% drop · plateau ~3 g/day
Total Cholesterol
−13.4 mg/dL
95% CI: −15.2 to −11.6
ApoB
−5 to −8%
Sahebkar 2019 meta · particle-count reduction, not size
Triglycerides
−6.3 mg/dL
95% CI: −9.4 to −3.3 · larger effect in dyslipidemic
sdLDL particles
−16%
Pediatric trial; signal in metabolic syndrome too
Systolic BP
−2.1 mmHg
95% CI: −3.3 to −0.9 · modest but consistent
HDL-C
+0.5 mg/dL
95% CI: +0.1 to +0.8 · clinically minor
Lp(a)
↓ (small)
Sahebkar 2019: significant reduction, but small magnitude. Not a primary Lp(a) tool.
Dose-Response
LDL-C reduction by daily intake
LDL Reduction vs Daily Dose (Demonty 2009 / Ras 2014)
Curve based on 84-141 trial arms meta-regression. Plateau emerges above ~3 g/day; modest additional benefit per gram beyond 2g.
Key dose insights
- 0.5 g/day: ~3–4% LDL drop (minimal)
- 1.0 g/day: ~6% LDL drop
- 2.0 g/day: ~10% LDL drop sweet spot
- 3.0 g/day: ~12% LDL drop (plateau begins)
- >3.0 g/day: diminishing returns; absorption saturates
Why the plateau? The intestinal sterol absorption pathway (NPC1L1 + ABCG5/G8 efflux) saturates. Once you displace the maximum competing dietary cholesterol you can, additional sterols add no benefit.
Mechanism
How they actually work
1 · Intestinal Displacement
Plant sterols/stanols are structural analogues of cholesterol. They incorporate into mixed micelles in the small intestinal lumen, physically displacing dietary and biliary cholesterol from absorption.
2 · ABCG5/G8 Efflux
The small amount of sterols that do enter enterocytes are pumped back into the gut lumen by ABCG5/ABCG8 transporters. This is why sitosterolemia (loss-of-function ABCG5/G8) causes massive sterol accumulation.
3 · Hepatic LDL-R Upregulation
Reduced cholesterol absorption → depleted hepatic cholesterol pool → SREBP-2 activation → increased LDL-receptor expression → enhanced LDL clearance from blood. This is the same downstream lever as statins, ezetimibe, and PCSK9 inhibitors — just upstream-different.
Sterols vs Stanols — the practical difference
Sterols (e.g., β-sitosterol, campesterol) have a double bond in the ring and are weakly absorbed (~0.5–2%) — meaning small amounts enter circulation, and these can be oxidized.
Stanols (e.g., sitostanol) are saturated (hydrogenated) versions — virtually unabsorbed (<0.04%) and cannot be oxidized. Equal LDL-lowering efficacy.
Stanols (e.g., sitostanol) are saturated (hydrogenated) versions — virtually unabsorbed (<0.04%) and cannot be oxidized. Equal LDL-lowering efficacy.
Practical implication: If the oxidized-phytosterol-atherogenicity concern bothers you, use stanols. Same LDL effect, no oxidation pathway. Brand: Benecol or any "plant stanol ester" product.
Lp(a) — Specific Analysis
What the data actually says
Sahebkar 2019 Meta-Analysis
- 12 effect sizes from 7 RCTs
- Outcome: Statistically significant reduction in Lp(a) (p = 0.017)
- Heterogeneity: I² = 0% (very consistent across trials)
- Effect size: small. WMD reported as −0.025 mg/dL — likely a unit transcription, but magnitude is clinically modest in any case
- Mechanism unclear — possibly via reduced hepatic apo(a) synthesis when cholesterol pool depletes
Caveat — Oxidized Phytosterol Binding
- Oxidized phytosterols (oxyphytosterols) preferentially bind to Lp(a) particles
- Lp(a) is already a carrier for oxidized phospholipids (its core pro-inflammatory mechanism)
- This argues for stanols, not sterols, if you have elevated Lp(a) — stanols can't oxidize
- Or sterols in capsule form (less oxidation than margarine spreads exposed to air/heat)
What it means
Bottom line for Lp(a): Plant stanols are not a primary Lp(a) intervention — the real Lp(a) lever is the upcoming siRNA class (Olpasiran, Lepodisiran, Pelacarsen) covered in your Lp(a) tracker. But the Sahebkar meta shows they don't worsen Lp(a) and may modestly improve it — they're at minimum Lp(a)-neutral, and the better form choice (stanols) is also more atomically safe for an elevated-Lp(a) phenotype.
Evidence Pyramid
What we actually know, by evidence quality
Tier 1 — Outcome Data
Nurses' Health Study + HPFS (Wang 2024) — n=213,992 prospective cohort, 5.5M person-years, 8,725 incident CAD cases.
Pooled HR for top vs bottom quintile total phytosterol intake: 0.93 (95% CI 0.86–1.01). Campesterol: 0.89 (0.82–0.96, p-trend 0.05). Nonlinear, plateau at ~30 mg/day campesterol intake (correction — earlier draft said 180 mg/day; verified against Wang 2024 full text May 2026). Modest CAD risk reduction at moderate dietary intake.
Pooled HR for top vs bottom quintile total phytosterol intake: 0.93 (95% CI 0.86–1.01). Campesterol: 0.89 (0.82–0.96, p-trend 0.05). Nonlinear, plateau at ~30 mg/day campesterol intake (correction — earlier draft said 180 mg/day; verified against Wang 2024 full text May 2026). Modest CAD risk reduction at moderate dietary intake.
2024 · AJCN
Tier 1 — Meta-Analyses
Yang 2024 — 109 RCTs. LDL −12.6 mg/dL, TC −13.4, TG −6.3, SBP −2.1 mmHg, DBP −0.8, HDL +0.5. All p<0.001 or p<0.05.
Demonty 2009 / Ras 2014 — Established the canonical dose-response curve. 84 trials → 141 trial arms.
Sahebkar 2019 (apolipoproteins) — ApoB significantly reduced; ApoB/A1 ratio improved.
Sahebkar 2019 (Lp(a)) — Small but significant Lp(a) reduction across 7 trials.
Demonty 2009 / Ras 2014 — Established the canonical dose-response curve. 84 trials → 141 trial arms.
Sahebkar 2019 (apolipoproteins) — ApoB significantly reduced; ApoB/A1 ratio improved.
Sahebkar 2019 (Lp(a)) — Small but significant Lp(a) reduction across 7 trials.
2009–2024
Tier 2 — Official Guidelines
EAS Consensus Panel 2014 (Gylling et al.) — European Atherosclerosis Society endorsement of 2 g/day for ~10% LDL reduction. Recommended in (1) high-cholesterol patients at intermediate/low CV risk not yet on pharma, (2) adjunct to statin/PCSK9i.
FDA health claim — May reduce risk of heart disease (since 2000).
EFSA health claim approved — for LDL reduction at 1.5–3 g/day.
FDA health claim — May reduce risk of heart disease (since 2000).
EFSA health claim approved — for LDL reduction at 1.5–3 g/day.
2014 Consensus
Tier 2 — Mechanistic / Combination RCTs
Psyllium + Plant Sterols combination (RCTs) — Significantly greater LDL reduction than either alone. 26% upregulation of LDL-receptors in circulating mononuclear cells. Modifies intravascular processing of lipoproteins, increases LDL uptake.
Plant sterols + Ezetimibe combination (RCT) — Mixed: one trial showed additive (combination −27.3% vs ezetimibe −19.1% alone); another showed no additive benefit. Likely competes for same NPC1L1 transporter.
Plant sterols + Ezetimibe combination (RCT) — Mixed: one trial showed additive (combination −27.3% vs ezetimibe −19.1% alone); another showed no additive benefit. Likely competes for same NPC1L1 transporter.
2007–2017
Tier 3 — MR Studies (Contested)
Helgadottir 2020 (Eur Heart J, vol 41, p 2618) — Genetically-predicted phytosterol absorption (via ABCG8 variants) → causally associated with CAD risk. (Earlier draft cited as 2022 — corrected.)
Critical counterargument (German Expert Panel 2023): ABCG5/G8 variants regulate all xenosterol uptake AND cholesterol absorption. The MR association may reflect increased LDL-C in carriers, not phytosterol toxicity per se (pleiotropy). MR design cannot disentangle these.
Critical counterargument (German Expert Panel 2023): ABCG5/G8 variants regulate all xenosterol uptake AND cholesterol absorption. The MR association may reflect increased LDL-C in carriers, not phytosterol toxicity per se (pleiotropy). MR design cannot disentangle these.
2022 / 2023 rebuttal
Tier 4 — Animal Data on Oxidized Sterols
Oxidized plant sterols in LDL-R−/+ mice — Increased proportion of severe atherosclerotic lesions.
Clinical relevance to humans consuming non-oxidized supplements is unclear. Resolved by using stanols (cannot oxidize) or capsule formulations (minimal oxidation exposure).
Clinical relevance to humans consuming non-oxidized supplements is unclear. Resolved by using stanols (cannot oxidize) or capsule formulations (minimal oxidation exposure).
2013
Tier 4 — Historical Observational Signal
PROCAM (Assmann 2006) — Top-quartile serum sitosterol → ~1.8× CHD HR. Confounded, observational, contradicted by subsequent meta-analyses.
Largely superseded by the Nurses'/HPFS prospective cohort showing the opposite signal at population-level intake.
Largely superseded by the Nurses'/HPFS prospective cohort showing the opposite signal at population-level intake.
2006
Honest Balance
What's the actual case for and against?
Case For (Steel-Manned)
- 109-RCT meta-analysis shows reliable ~10% LDL drop at 2 g/day — equivalent to a low-dose statin.
- EAS official endorsement for exactly this use case (intermediate-risk patient not yet on pharma).
- Prospective cohort (n=213,992) shows modest CAD risk reduction at moderate intake. Real outcome data, not just biomarkers.
- Synergy with psyllium documented mechanistically (LDL-R upregulation +26%) — these two are complementary, not duplicative.
- ApoB reduction is real (5–8%) — meaningful for an ApoB-driven phenotype.
- Lp(a) doesn't worsen, may modestly improve per meta-analysis.
- BP, sdLDL, glucose all show modest favourable effects in some trials.
- Safety profile excellent — 25+ years of population use, no signal in any outcome trial.
- Cheap — generic capsules ~$15–25/month.
Case Against (Steel-Manned)
- No randomized hard-outcome trial ever conducted. All efficacy is biomarker-based; the cohort outcome data is observational.
- Helgadottir 2022 MR study raises a real causal signal for phytosterol-mediated CAD risk — even if confounded by ABCG5/8 pleiotropy, it can't be fully dismissed.
- Oxidized phytosterols (oxyphytosterols) are atherogenic in animal models — relevance to humans using oxidized-sterol products is unclear. Eliminated by using stanols or capsule form.
- Mild fat-soluble vitamin / carotenoid malabsorption (~10–20% β-carotene reduction). Solvable with higher Vit D, varied diet.
- Diminishing returns above 3 g/day — overdosing is wasteful.
- Competes with ezetimibe on NPC1L1 — if you ever start ezetimibe, drop the sterols.
- Marginal vs. true pharma — a 10–12% LDL drop is a fraction of what statins (40–50%), ezetimibe (15–20%), PCSK9i (50–60%) or future siRNAs deliver.
- If you carry ABCG5/G8 risk variants the calculus genuinely shifts negative. (Not you — confirmed wild-type via VCF 18 May 2026.)
Stacking
How plant sterols compose with other lipid tools
Approximate Additive LDL-C Reduction (vs untreated baseline)
Stacked effects assume same patient, same baseline. Real-world effects vary ±30% individually.
Product Selection
Top 3 Picks — Ranked for Your Phenotype (May 2026)
Ranking criteria, in order: (1) clinical fit for your elevated Lp(a) — stanols / stanol-blends preferred over pure sterols; (2) third-party verification (USP > NSF > brand COA); (3) formulation purity; (4) value. Form factor (chews vs. capsules) and broad form-comparison table are deferred to the Stacking and Verdict sections.
1
NOW Foods · Softgels · 180 ct ~ $25–30 · iHerb / Amazon / Vitacost
Hits 2 g cleanly (4 sg)
CardioAid®-S (BASF, RCT-studied)
+ EPA/DHA bonus
~$20/month
Per 2-sg serving
1,000 mg phytosterol esters
Target dose
4 softgels/day = 2.0 g
Form
Esterified, fish-oil base
Cost/g phytosterol
~ $0.33
Why this is #1 — best overall
The simplest, most effective answer to the actual question: 4 softgels per day hits the clinical 2 g/day target exactly at the cheapest cost per gram of any reputable product. CardioAid®-S is the BASF-branded phytosterol ester blend used in the majority of the published RCT literature on plant sterols — it's the actual ingredient studied, not a generic equivalent. Esterified sterols incorporate into mixed micelles more efficiently than free sterols (better bioavailability). Fish-oil base is a real bonus for an ApoB-heavy phenotype: small EPA/DHA dose reduces hepatic VLDL secretion (modest additive ApoB benefit) and improves phytosterol solubility. NOW has one of the more rigorous in-house analytical labs in the mass-market supplement space (NPA GMP certified, no USP seal). No sugar, no chew format, no excipient bloat.
Pros
- Hits 2 g cleanly at 4 softgels/day — lowest pill count to dose
- Cheapest per gram of phytosterol on the list
- CardioAid-S is the RCT-studied ingredient
- Esterified form (better micelle incorporation)
- Bonus EPA/DHA from fish-oil base
- ~4.5★ on iHerb across thousands of reviews
- NOW QC reputation is strong
Cons
- No USP Verified seal (NPA GMP only)
- Pure sterols (no stanols) — see TLDR caveat re: Lp(a) mechanism
- Fish-oil base: minor fishy aftertaste reported by some users
- Large softgel — some find swallowing 4/day awkward
Latest user/expert signal (May 2026): Sustained 4.5★+ on iHerb (180-ct SKU has thousands of reviews) and Amazon (~13,000 reviews). 2025 reviewers consistently report LDL normalization within 4–8 weeks at full dose. High repeat-purchase rate. Make sure you get the CardioAid-S + Fish Oil SKU — NOW also sells a generic "Beta-Sitosterol" 90 mg capsule which is too low-dose for cholesterol use.
2
Pharmavite · Softgels · 210 ct (Costco) ~ $40 · Amazon, CVS, Walgreens
USP Verified ✓
Reducol™ (Sterols + Stanols)
ConsumerLab Approved
Costco-bulk Value
Per 2-sg serving
900 mg ester (~540 mg free)
Target dose
6 softgels/day = ~1.6 g free
Form
Reducol blend, soy-derived
Cost/g phytosterol
~ $0.45
Why this is #2 — gold-standard verification
USP Verification is the highest-confidence third-party seal in US supplements: independently audited label accuracy, dissolution, contaminant testing, and GMP facility audit. CholestOff Plus is one of very few phytosterol products carrying it — for quarterly lab tracking, that matters. Reducol™ contains stanols as well as sterols (Nature Made/Raisio do not publish the exact ratio), so it's not pure-sterol, giving partial Lp(a)-oxidation credit while keeping the gold-standard seal. Dosing note: the label's "1,800 mg/day" is ester weight — esters are ~60% active by mass, so 4 softgels = ~1.1 g free sterol equivalent. For the clinical 2 g target, take 6 softgels split across 3 meals. The pill count is its main weakness vs. #1.
Pros
- Only USP-Verified product on the shortlist
- Contains both sterols and stanols (Reducol)
- Costco 210-ct bottle = best per-pill value
- Widely stocked (CVS, Walgreens, supermarket)
- ConsumerLab top-tier approved
- Decades of consumer track record
Cons
- Label dose is ester weight — 4 sg = ~1.1 g free, sub-therapeutic
- Need 6 softgels/day for ~1.6 g free (still under 2 g target)
- Soy-derived (irrelevant for most)
- Highest pill count of the three
Latest user/expert signal (May 2026): ~4.6★ on Amazon (~4,200 reviews). ConsumerLab places it in top tier of approved cholesterol-lowering supplements. 2025 long-form reviews report 8–15% LDL drops over 8–12 weeks at full dose. Most common failure mode: users take only the 2-softgel label "serving" and see no effect — the 6/day dose is the lever.
3
Solgar · Softgels · 100 ct ~ $25–30 · iHerb / Vitacost
4 sg = 2 g (clean)
Full Sterol Spectrum
Kosher / Gluten-Free
Premium Brand
Per 2-sg serving
1,000 mg phytosterols
Target dose
4 softgels/day = 2.0 g
Form
Esterified blend, soy-derived
Cost/g phytosterol
~ $0.40
Why this earns the #3 slot — premium clean alternative
Solgar is one of the older and more trusted European supplement brands — manufactured to GMP standards with no artificial sweeteners, preservatives, colors, or flavors. Hits the 2 g/day target cleanly at 4 softgels/day (same pill count as the #1 pick) and contains the full phytosterol spectrum: β-sitosterol, campesterol, stigmasterol, and brassicasterol. No fish-oil base — choose this over the #1 pick if you don't want EPA/DHA in the same product, are already taking fish oil separately, or have any aversion to the fishy aftertaste. Kosher and gluten-free certified. Slightly more expensive than NOW per gram but cleanest-formulation of the cap-form picks (no excipient bloat, no chew format, no sugar).
Pros
- Hits 2 g cleanly at 4 softgels/day
- Full phytosterol spectrum (4 sterols)
- No fish-oil base — clean separation if you take EPA/DHA separately
- No artificial sweeteners, colors, flavors, or preservatives
- Kosher, gluten-free
- Trusted European brand (30+ years)
Cons
- No USP seal
- Pure sterols (no stanols)
- Soy-derived (irrelevant for most)
- ~20% more expensive per gram than NOW
Latest user/expert signal (May 2026): ~4.5★ on iHerb (~500 reviews). Solgar's QC reputation is one of the strongest in the legacy-supplement space; long product history with no recalls or label-vs-test discrepancies. Choose if you specifically want a fish-oil-free clean formulation in cap form at 4 sg/day.
Side-by-Side Comparison
| #1 NOW CardioAid-S + Fish Oil | #2 Nature Made CholestOff Plus | #3 Solgar Phytosterol Complex | |
|---|---|---|---|
| Active form | CardioAid-S sterol esters (soy) | Reducol (sterols + stanols, soy) | Sterol esters (soy) |
| Daily dose for 2 g | 4 softgels = 2.0 g | 6 softgels = ~1.6 g free | 4 softgels = 2.0 g |
| Third-party seal | NPA GMP | USP Verified ✓ | GMP, Kosher, gluten-free |
| Stanol content | None (pure sterols) | Partial (Reducol) | None (pure sterols) |
| Pill burden | 4/day | 6/day | 4/day |
| Cost/g phytosterol | ~ $0.33 | ~ $0.45 | ~ $0.40 |
| Bonus actives | EPA/DHA (small dose) | — | — |
| Format issues | Fishy aftertaste (some) | Highest pill count | None |
| Where to buy | iHerb, Amazon, Vitacost | Costco, Amazon, CVS | iHerb, Vitacost, Whole Foods |
| Best for | Best overall — 2 g clean + cheap | Verification-first / Costco buyer | Fish-oil-free clean alternative |
Dosing Protocol — Whichever You Pick
Daily target
2 g free sterol/stanol equivalent, split in 2–3 doses with meals. The 8–10% LDL-C and 5–8% ApoB reduction is dose-dependent up to ~2.5 g/day, then plateaus.
Timing
Always with food containing fat. Phytosterols only displace cholesterol if they reach the mixed-micelle phase in the small intestine. Empty-stomach dosing wastes the dose.
Split schedule
2–3 doses across meals (lunch + dinner minimum). Single-dose taken once daily is ~30% less effective in trials.
Time to effect
Measurable LDL-C drop by week 2–4; steady-state by week 8. Re-check ApoB, LDL-C, Lp(a), HbA1c at week 12.
Stack guardrails
Stop sterols if you start ezetimibe — both compete for NPC1L1 and ezetimibe wins. Layers well with statin, PCSK9i, bempedoic acid, and psyllium.
Vitamin offset
Plant sterols mildly reduce β-carotene absorption (~15–20%). Offset by bumping Vit D3 to 4,000–5,000 IU/day and eating varied colored vegetables.
Verdict
Recommendation for your phenotype
Add plant sterols/stanols 2 g/day as a nutraceutical bridge
Weighing (a) the 109-RCT meta-analysis showing clear LDL/ApoB/BP effects, (b) the 213,992-person cohort showing modest CAD risk reduction, (c) the EAS 2014 official endorsement at 2 g/day, (d) your wild-type ABCG5/8 status removing the genetic safety question, (e) the documented psyllium synergy, and (f) the honest 2025 ESC/EAS Update caveat that there are zero CV outcome RCTs — net verdict is add it as a bridge nutraceutical, prefer a stanol-containing product.
Concrete protocol for you:
- Primary pick: NOW Foods Beta-Sitosterol with CardioAid-S + Fish Oil — 4 softgels/day split across 2–3 meals = 2.0 g cleanly. Cheapest per gram, CardioAid-S is the RCT-studied ingredient, fish oil base = bonus EPA/DHA for ApoB.
If you prioritize USP verification: Nature Made CholestOff Plus — 6 sg/day for ~1.6 g free. Reducol blend contains stanols. Costco bulk best value.
If you want fish-oil-free alternative: Solgar Phytosterol Complex — 4 sg/day = 2.0 g, premium clean European brand. - Stack with psyllium 10 g/day (already in your protocol). Documented mechanistic synergy via LDL-receptor upregulation — complementary, not duplicative.
- Bump Vit D3 to 4,000–5,000 IU/day to offset the small fat-soluble vitamin malabsorption. Eat a diverse colourful diet for carotenoid sufficiency.
- Re-test ApoB, LDL-C, Lp(a), HbA1c at 12 weeks (week 8 if you want earlier signal). Expected: ApoB drop ~13–18% combined with psyllium; LDL-C drop ~15–20%; Lp(a) minimal change; HbA1c psyllium-driven only.
- If you start ezetimibe in the future: stop the sterols. They compete for the same NPC1L1 transporter.
- Long-term: not a substitute for real pharma levers (PCSK9i, future Lp(a) siRNA — see your Lp(a) tracker). These are an adjunct that closes part of the nutraceutical gap before you need pharma — or supplements pharma when you're on it.
Honesty note: A 10–12% LDL drop and 5–8% ApoB drop from a supplement is modest, not transformative. For your phenotype (ApoB 108 → target <80 mg/dL, Lp(a) 90 nmol/L) the real risk-driver is Lp(a), and the real future-lever is in your Lp(a) tracker. Plant sterols + psyllium are reasonable nutraceutical bridges, not solutions.